NEW BRUNSWICK, N.J., May 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will provide a pre-recorded webcast for financial analysts on Friday, May 9 at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's (APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on investigational tapentadol immediate release (IR), a novel centrally acting oral analgesic, will be presented for the first time at APS.

A pre-recorded Webcast, with the lead tapentadol researchers, will be made available concurrent to the data presentations being made during the poster session at APS. Pre-registration is not required to view the webcast/podcast.

The presentation will provide an overview on tapentadol IR and review data from the following clinical posters:

    -- Efficacy of Tapentadol Immediate Release in Patients With Pain After
       Bunionectomy
    -- Analgesic Efficacy of Tapentadol Immediate Release in Patients With
       Pain From End-Stage Joint Disease
    -- Tapentadol Immediate Release is Associated With Improved
       Gastrointestinal Tolerability Compared With Oxycodone Immediate Release
       Over 90 Days in Patients With Lower Back or Osteoarthritis Pain

Close window | Back to top